The widespread use of smartphones and the internet has enabled self-monitoring and more hybrid-care models. The COVID-19 pandemic has further accelerated remote monitoring, including in the heterogenous and often vulnerable group of patients with interstitial lung diseases (ILDs). Home monitoring in ILD has the potential to improve access to specialist care, reduce the burden on health-care systems, improve quality of life for patients, identify acute and chronic disease worsening, guide treatment decisions, and simplify clinical trials. Home spirometry has been used in ILD for several years and studies with other devices (such as pulse oximeters, activity trackers, and cough monitors) have emerged. At the same time, challenges have surfaced, including technical, analytical, and implementational issues. In this Series paper, we provide an overview of experiences with home monitoring in ILD, address the challenges and limitations for both care and research, and provide future perspectives. VIDEO ABSTRACT.
Competing Interests: Declaration of interests MSW reports grants from Boehringer Ingelheim, Hoffman la Roche, The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, and The Dutch Pulmonary Fibrosis Foundation; consulting fees from Boehringer Ingelheim, Hoffman la Roche, Galapagos, Bristol Myers Squibb (BMS), Galecto, Respivant, Nerretherapeutics, PureTech Health, Kinevant Sciences, Molecure, Horizontherapeutics, and CSL Behring; speaker fees from Boehringer Ingelheim, Hoffman la Roche, and Novartis; support for attending meetings from Boehringer Ingelheim, Hoffman la Roche, and Galapagos; and DSMB fees from Savara and Galapagos. All grant and fees were paid to her institution. CCM reports grants from Boehringer Ingelheim and AstraZeneca; and speakers fees from Boehringer Ingelheim and Hoffman-la Roche. All grants and fees were paid to her institution. KAJ reports grants from Three Lakes Foundation, Chest Foundation, University of Calgary, and University Hospital Foundation; consulting fees from Boehringer Ingelheim, Hoffman-La Roche, Pliant, and Three Lakes Foundation; and speaker fees from Boehringer Ingelheim and Hoffman-La Roche. PDJ reports grants from the Pulmonary Foundation Scholar Award, Chest/ATS Foundation COVID19 diversity grant, VCU DOIM Pilot award, and NIH Fogarty Fellowship; and speaker fees from the Virginia Association of Community Psychiatric Nurses. YHK reports grants from the National Health and Medical Research Council Investigator Grant, Centre of Research Excellence in Pulmonary Fibrosis PACT Grant-in-Aid and CREATE Grant-in-Aid, Austin Medical Research Foundation Research Grant, Royal Australasian College of Physicians Research Establishment Fellowship and Robert and Elizabeth Albert Travel Grant, and Lung Foundation Australia-Lizotte Family Award for Idiopathic Pulmonary Fibrosis Research. YK reports speaker fees from Asahi Kasei Pharma, Shionogi, Boehringer Ingelheim, AstraZeneca, Eisai, KYORIN Pharmaceutical, Mitsubishi Tanabe Pharma, and Novartis Pharma; and advisory board fees from Shionogi, Boehringer Ingelheim, Taiho Pharmaceutical, Chugai Pharmaceutical, Janssen Pharmaceutical, and Healios. GCT reports consulting fees from Boehringer Ingelheim and Knight pharmaceuticals; and speaker fees from Boehringer Ingelheim, Tutear, Raffo, AstraZeneca and Knight pharmaceuticals. BEV reports travel support from Boehringer Ingelheim, Raffo, Roche, Bago, and Tutear; and advisory board fees from Boehringer Ingelheim, and Tutear. RNvZ-S reports consulting fees from Aspen/GlaxoSmithKline (GSK), Novartis, and Boehringer Ingelheim; speaker fees from Novartis, Pfizer, Johnson & Johnson, MSD, AstraZeneca, Hoffman la Roche, Philips, and Cipla. MK reports grants from Boehringer Ingelheim and Hoffman-La Roche; consulting fees from Boehringer Ingelheim, Hoffman-La Roche, and Galapagos; and speaker fees from Boehringer Ingelheim and Hoffman-La Roche. TMM reports consulting fees from Boehringer Ingelheim, Roche/Genentech, AstraZeneca, Bayer, Blade Therapeutics, BMS, Galapagos, Galecto, GSK, IQVIA, Pliant, Respivant, Theravance, and Veracyte; and speaker fees from Boehringer Ingelheim and Roche/Genentech. SKR and PvdW declare no competing interests.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)